Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina et al

Ann Rheum Dis. 2021 May;80(5):e80. doi: 10.1136/annrheumdis-2020-218147. Epub 2020 Aug 18.
No abstract available

Keywords: ankylosing; antirheumatic agents; arthritis; biological therapy; infectious; rheumatoid; spondylitis.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Psoriatic* / drug therapy
  • COVID-19*
  • Etanercept / therapeutic use
  • Humans
  • SARS-CoV-2
  • Spondylarthritis* / drug therapy
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Ustekinumab / therapeutic use

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Ustekinumab
  • Etanercept